Helixmith マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Ji-Wook Jeong

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans

Oct 18

Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?

Feb 19

CEO（最高経営責任者

Ji-Wook Jeong

less than a year

在職期間

Ji-Wook Jeong is CEO & President of Helixmith Co. Ltd from 2024.

Helixmith マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

No independent directors

No independent directors

Recent updates

New minor risk - Market cap size

Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans

Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding

Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding

New minor risk - Share price stability

Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.

Price target decreased to ₩19,900

No independent directors

Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)

Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)

Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19

First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)

Price target increased to ₩29,182

Price target decreased to ₩26,529

No independent directors

Price target decreased to ₩26,529

Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOS

Price target decreased to ₩33,000

New 90-day low: ₩24,550

Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?

Wacker Chemie AG (XTRA:WCH) entered into an agreement to acquire Genopis Inc. from Medivate Partners LLC and Helixmith Co., Ltd (KOSDAQ:A084990) for $39 million.

Helixmith Co., Ltd announced that it has received KRW 20 billion in funding

Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in funding

Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.

New 90-day low: ₩30,750

Helixmith to Be Deleted from Other OTC

New 90-day low: ₩41,800

New 90-day low - ₩52,000

New 90-day low - ₩56,500

CEO（最高経営責任者

在職期間

Helixmith マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

No independent directors

No independent directors

Recent updates

New minor risk - Market cap size

Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans

Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding

Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding

New minor risk - Share price stability

Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.

Price target decreased to ₩19,900

No independent directors

Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)

Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)

Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19

First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)

Price target increased to ₩29,182

Price target decreased to ₩26,529

No independent directors

Price target decreased to ₩26,529

Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOS

Price target decreased to ₩33,000

New 90-day low: ₩24,550

Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?

Wacker Chemie AG (XTRA:WCH) entered into an agreement to acquire Genopis Inc. from Medivate Partners LLC and Helixmith Co., Ltd (KOSDAQ:A084990) for $39 million.

Helixmith Co., Ltd announced that it has received KRW 20 billion in funding

Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in funding

Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.

New 90-day low: ₩30,750

Helixmith to Be Deleted from Other OTC

New 90-day low: ₩41,800

New 90-day low - ₩52,000

New 90-day low - ₩56,500

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04